ClinicalTrials.gg
Not yet recruitingNCT07051447RADAR-KUpdated Nov 17, 2026

The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial

An interventional study of PKRxHD and Dialysis in End Stage Kidney Disease, sponsored by NYU Langone Health. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

Updated Nov 17, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This will be a randomized controlled pilot trial comparing usual care to a precision approach to dialysis potassium prescribing. The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).

02

Conditions studied

  • End Stage Kidney Disease
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's planned enrollment of 120 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.

Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing in-center, 3x/weekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days
  • Age at least 21 years
  • Prescribed HD time up to 15 hours/ week

Exclusion criteria

Exclusion Criteria:

  • Incarcerated
  • of 1 year or less
  • Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less
  • Cognitive condition that precludes consent
  • Severe anemia ( \< 8.0 g/dL) within 30 days
  • K concentration of 7.0 mEq/L or more within 60 days
  • Pregnant women
  • Women of actively trying to conceive unwilling to use
  • Participation in other interventional studies within 30 days prior to enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Precision approach to K Prescription for HD (PKRxHD)

    Participants will receive a novel dialysate potassium (K) management strategy.

    Other: PKRxHD · Procedure: Dialysis

  • Active comparator
    Usual Care

    Standard dialysis potassium prescribing.

    Procedure: Dialysis

Interventions

  • OtherPKRxHD

    The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).

  • ProcedureDialysis

    Standard of care dialysis.

06

What researchers measure

Primary outcomes

  1. Intervention Adherence

    Measured as the proportion of hemodialysis (HD) treatments in the experimental arm completed per protocol with both pre-HD point of care testing and appropriate adjustment of the dialysate prescription.

    Time frame: Up to Week 24

  2. Recruitment Feasibility

    Measured as the proportion of eligible patients enrolled successfully.

    Time frame: Baseline

  3. Incidence Rate of Pre-HD Hyperkalemia

    Hyperkalemia is defined as K≥ 6.4 mEq/L.

    Time frame: Baseline

  4. Post-HD Recovery Time

    Measured as the average time to recovery following each HD session.

    Time frame: Up to Week 24

Secondary outcomes

  1. Incidence Rate of Post-HD Hyperkalemia Incidence Rate

    Hyperkalemia is defined as K≥ 6.4 mEq/L.

    Time frame: Up to Week 24

  2. Incidence Rate of Moderate Hyperkalemia

    Hyperkalemia is defined as K≥ 3.0 mEq/L.

    Time frame: Up to Week 24

  3. Incidence Rate of Peri-Dialytic Cramping

    Time frame: Up to Week 24

  4. Incidence Rate of Intradialytic Hypotension

    Intradialytic hypotension will be defined as the proportion of HD sessions with intradialytic systolic blood pressure\<90 mmHg, as this definition best captures associations with mortality according to current guidelines.

    Time frame: Up to Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.Charytan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2027; primary completion for Feb 2029, 16 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 16 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Oct 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartEst.
Oct 2027was Aug 2025
Primary completionEst.
Feb 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2025→Oct 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Aug 1, 2025→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07051447
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Oct 2027 (estimated)
Primary completion
Feb 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

David Charytan, MD
Contact
David.Charytan@nyulangone.org
212-263-0705
Zoe Rimler
Contact
Zoe.Rimler@nyulangone.org
212-263-2544

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion